Lexicon Pharmaceuticals (LXRX) Common Equity (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Common Equity data on file, last reported at $202.9 million in Q1 2026.

• Common Equity for Q1 2026 came in at $202.9 million, up 64.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $202.9 million (up 64.88% YoY), and the FY2025 annual result was $107.5 million, down 26.32% from the prior year.
• Common Equity grew to $202.9 million in Q1 2026 per LXRX's latest filing, from $107.5 million in the prior quarter.
• Over five years, Common Equity peaked at $288.9 million in Q1 2024 and troughed at $70.8 million in Q2 2022.
• A 5-year average of $145.2 million and a median of $129.4 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity jumped 228.09% in 2024, then sank 57.41% in 2025.
• A 5-year view of Common Equity shows it stood at $117.1 million in 2022, then decreased by 20.5% to $93.1 million in 2023, then surged by 56.75% to $146.0 million in 2024, then decreased by 26.32% to $107.5 million in 2025, then jumped by 88.64% to $202.9 million in 2026.
• Business Quant data shows LXRX's Common Equity at $202.9 million in Q1 2026, $107.5 million in Q4 2025, and $120.2 million in Q3 2025.